SCHEMBL3652136

SCHEMBL3652136

c1ccc2cc(-c3ccc4ncn(C5CCNCC5)c4n3)ccc2c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCI P41743 1/20 0.43
NR1H4 Q96RI1 1/20 0.43
MAPK14 Q16539 12/20 0.41
PIK3CA P42336 1/20 0.41
MTOR P42345 1/20 0.41
BRD4 O60885 1/20 0.41
JAK2 O60674 1/20 0.40
JAK1 P23458 1/20 0.40
MAPK13 O15264 2/20 0.39
MAPK12 P53778 2/20 0.39
MAPK11 Q15759 2/20 0.39
RIPK2 O43353 1/20 0.39
DYRK3 O43781 1/20 0.39
PRKD3 O94806 1/20 0.39
MAP4K4 O95819 1/20 0.39
PRKCG P05129 1/20 0.39
LCK P06239 1/20 0.39
LYN P07948 1/20 0.39
RET P07949 1/20 0.39
PIM1 P11309 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3647369 0.81 JAK1 (0.39) PIK3CAMTORJAK1DKK1
SCHEMBL3644182 0.81 NR1H4 (0.43) PRKCINR1H4MAPK14BRD4JAK2
SCHEMBL3649161 0.78 HCAR1 (0.50) PIK3CAMTOR
SCHEMBL3648302 0.78 PIK3CA (0.43) NR1H4PIK3CAMTORDKK1
SCHEMBL3647759 0.76 PRKCI (0.44) PRKCINR1H4MAPK14PIK3CAMTOR
SCHEMBL3651945 0.75 NR1H4 (0.48) NR1H4MAPK14BRD4DKK1
SCHEMBL3651846 0.74 PIK3CA (0.40) NR1H4PIK3CAMTORMAPK9DKK1
SCHEMBL3652076 0.73 DYRK1A (0.61) PIK3CAMTORKDRDKK1
SCHEMBL3645100 0.73 PIK3CA (0.41) NR1H4MAPK14PIK3CAMTORMAPK11
SCHEMBL3651843 0.73 PIK3CA (0.39) NR1H4PIK3CAMTORDKK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2185556-A1 IMIDAZOPYRIDINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM Wyeth a Corporation of the State of Delaware (US) 2010-05-19 EP claimed
US-20090069319-A1 IMIDAZOPYRIDINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM WYETH (US) 2009-03-12 US claimed
WO-2009029609-A1 IMIDAZOPYRIDINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM WYETH (US) 2009-03-05 WO claimed
US-20090069319-A1 IMIDAZOPYRIDINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM WYETH (US) 2009-03-12 US disclosed
US-20090069319-A1 IMIDAZOPYRIDINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM WYETH (US) 2009-03-12 US disclosed
US-20090069319-A1 IMIDAZOPYRIDINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM WYETH (US) 2009-03-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069319-A1 IMIDAZOPYRIDINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM WNT1, CTNNB1, WNT3A PRKCI 304/4885NR1H4 374/4885MAPK14 888/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.